vVARDIS Targets $214 Million IPO With a Pitch to Change Cavity Treatment

Swiss dental company vVARDIS Holding AG (NYSE: VVVV) plans to offer 9.52 million shares at $21–$24, raising approximately $214.3 million at the $22.50 midpoint, with an estimated economic equity valuation of $1.29 billion, including midpoint anti-dilution shares. Goldman Sachs and J.P. Morgan lead the offering, joined by William Blair, UBS and Deutsche Bank.

The Business: Earlier Intervention

vVARDIS markets Curodont, a peptide-based treatment designed to repair early-stage tooth decay. Its application is limited to early lesions; advanced cavities can still require conventional restoration.

The investment question is whether dentists can make earlier intervention a routine part of patient care. A product that patients accept, practices repeatedly purchase and clinicians incorporate into their workflow could build a durable business. Initial adoption matters, but repeat usage will be the stronger test.

The first-half comparison shows operating leverage: revenue more than tripled while operating losses narrowed. However, investors should distinguish attractive product economics from company profitability. Sales, education and infrastructure spending still absorb more than the gross profit generated.

Preliminary Update

Nine-month 2026 estimates include $47.7–$49.2 million revenue, approximately 86% gross margin, $39.7–$41.3 million net losses, and $9.2–$9.4 million adjusted EBITDA losses. These figures are preliminary.

Subtracting reported first-half results implies approximately $19.1–$20.6 million in third-quarter revenue